Wedbush Initiates Coverage on Solventum (NYSE:SOLV)

Wedbush began coverage on shares of Solventum (NYSE:SOLV) in a research note issued on Friday, MarketBeat reports. The firm set an “outperform” rating and a $94.00 price target on the stock. Wedbush’s target price suggests a potential upside of 26.35% from the stock’s current price.

SOLV has been the subject of a number of other reports. Wall Street Zen downgraded shares of Solventum from a “buy” rating to a “hold” rating in a research note on Sunday, March 8th. Piper Sandler dropped their target price on shares of Solventum from $98.00 to $92.00 and set an “overweight” rating for the company in a research report on Friday, April 17th. BTIG Research reaffirmed a “buy” rating and issued a $89.00 price target on shares of Solventum in a research note on Wednesday, May 6th. Wells Fargo & Company reduced their price target on shares of Solventum from $83.00 to $70.00 and set an “equal weight” rating on the stock in a research report on Wednesday, May 6th. Finally, Rothschild & Co Redburn began coverage on Solventum in a report on Tuesday, March 24th. They set a “sell” rating and a $60.00 price objective on the stock. Eight equities research analysts have rated the stock with a Buy rating, five have given a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus target price of $84.25.

Solventum Stock Performance

NYSE:SOLV opened at $74.40 on Friday. The stock has a market capitalization of $12.88 billion, a P/E ratio of 9.12, a price-to-earnings-growth ratio of 1.15 and a beta of 0.59. The company has a current ratio of 1.07, a quick ratio of 0.75 and a debt-to-equity ratio of 0.96. Solventum has a 1 year low of $62.38 and a 1 year high of $88.20. The firm has a 50 day moving average of $67.86 and a 200-day moving average of $74.57.

Solventum (NYSE:SOLV) last released its quarterly earnings results on Tuesday, May 5th. The company reported $1.48 earnings per share for the quarter, beating analysts’ consensus estimates of $1.35 by $0.13. Solventum had a return on equity of 23.51% and a net margin of 17.33%.The firm had revenue of $2.01 billion during the quarter, compared to analysts’ expectations of $1.97 billion. During the same period last year, the firm posted $1.34 EPS. The business’s revenue was down 3.0% on a year-over-year basis. Solventum has set its FY 2026 guidance at 6.600-6.600 EPS. As a group, sell-side analysts anticipate that Solventum will post 6.58 EPS for the current fiscal year.

Insider Buying and Selling

In other Solventum news, Director Amy Mcbride Wendell purchased 1,475 shares of the business’s stock in a transaction on Tuesday, March 10th. The shares were purchased at an average cost of $68.03 per share, with a total value of $100,344.25. Following the transaction, the director directly owned 5,039 shares of the company’s stock, valued at $342,803.17. This represents a 41.39% increase in their position. The purchase was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. 0.24% of the stock is owned by company insiders.

Institutional Inflows and Outflows

Hedge funds have recently bought and sold shares of the stock. Healthcare of Ontario Pension Plan Trust Fund grew its stake in shares of Solventum by 59.0% in the first quarter. Healthcare of Ontario Pension Plan Trust Fund now owns 9,265 shares of the company’s stock valued at $605,000 after buying an additional 3,437 shares in the last quarter. Sei Investments Co. lifted its position in shares of Solventum by 335.0% in the first quarter. Sei Investments Co. now owns 240,581 shares of the company’s stock valued at $15,711,000 after buying an additional 185,271 shares during the last quarter. Lido Advisors LLC boosted its stake in shares of Solventum by 13.0% during the 1st quarter. Lido Advisors LLC now owns 8,922 shares of the company’s stock worth $583,000 after acquiring an additional 1,023 shares during the period. State of Wyoming increased its holdings in shares of Solventum by 768.1% during the 1st quarter. State of Wyoming now owns 6,363 shares of the company’s stock worth $416,000 after acquiring an additional 5,630 shares during the last quarter. Finally, Cetera Investment Advisers increased its holdings in shares of Solventum by 5.0% during the 1st quarter. Cetera Investment Advisers now owns 45,739 shares of the company’s stock worth $2,987,000 after acquiring an additional 2,166 shares during the last quarter.

Solventum Company Profile

Solventum Corporation, a healthcare company, engages in the developing, manufacturing, and commercializing a portfolio of solutions to address critical customer and patient needs. It operates through four segments: Medsurg, Dental Solutions, Health Information Systems, and Purification and Filtration. The Medsurg segment is a provider of solutions including advanced wound care, I.V. site management, sterilization assurance, temperature management, surgical supplies, stethoscopes, and medical electrodes.